Zivo Bioscience Reports 468% Revenue Increase to $157,220, Faces $13.4 Million Net Loss

Zivo Bioscience, Inc. reported a significant increase in revenue for the fiscal year ending December 31, 2024, with total revenue reaching $157,220, compared to $27,650 in the previous year, marking an increase of approximately 468%. This growth was primarily driven by increased product volume, although it was partially offset by lower selling prices. The company's cost of goods sold also rose to $108,268 from $16,040, reflecting the higher volume of product sold. Despite the revenue growth, Zivo reported a net loss of $13.4 million for 2024, up from a loss of $7.8 million in 2023, indicating ongoing challenges in achieving profitability.

In terms of operational developments, Zivo has made strides in its strategic initiatives, particularly in the therapeutic and nutritional sectors. The company has focused on developing bioactive extracts from its proprietary algal culture, targeting various health applications in both human and animal health. Notably, Zivo has entered into a contract manufacturing agreement with Alimenta Algae in Peru, which is expected to enhance its production capabilities. The partnership aims to scale up production to meet anticipated demand, with plans to reach full capacity by 2027, producing approximately 100,000 kg of algae annually.

Zivo's employee headcount remained stable, with seven full-time employees as of December 31, 2024. The company has emphasized the importance of retaining key personnel to drive its research and development efforts. However, it continues to face challenges related to its financial health, as indicated by its accumulated deficit of approximately $137 million. The company’s financial statements have been prepared under the assumption that it will continue as a going concern, although there is substantial doubt about its ability to do so without securing additional funding.

Looking ahead, Zivo plans to pursue additional funding through public or private equity or debt financing to support its ongoing operations and product development initiatives. The company has acknowledged the need for substantial additional financing to achieve its goals, particularly as it continues to incur significant expenses related to research and development. The management's outlook remains cautious, emphasizing the necessity of securing adequate capital to sustain operations and advance its product pipeline.

Overall, Zivo Bioscience is navigating a complex landscape as it seeks to capitalize on its proprietary algal technology while addressing financial and operational challenges. The company’s future performance will depend on its ability to secure funding, successfully scale production, and achieve market acceptance for its innovative products.